Skip to main content
Top
Published in: Cancer Imaging 1/2019

Open Access 01-12-2019 | Computed Tomography | Case series

The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!

Authors: Te-Jui Hung, Luke McLean, Catherine Mitchell, Claire Pascoe, Nathan Lawrentschuk, Declan G. Murphy, Amir Iravani, Dalveer Singh, Michael S. Hofman, Lamiaa Zidan, Tim Akhurst, Jeremy Lewin, Rodney J. Hicks

Published in: Cancer Imaging | Issue 1/2019

Login to get access

Abstract

Background

Testicular germ cell tumour is the commonest malignancy affecting males aged between 15 and 35, with an increased relative risk amongst those with a history of cryptorchidism. In patients presenting with locoregional metastatic disease, retroperitoneal and pelvic soft tissue masses are common findings on ultrasound and computed tomography, which has several differential diagnoses within this demographic cohort. On staging 18F-FDG-PET/CT, understanding the typical testicular lymphatic drainage pathway facilitates prompt recognition of the pathognomonic constellation of unilateral absence of testicular scrotal activity, and FDG-avid nodal masses along the drainage pathway. We describe the cases of three young males presenting with abdominopelvic masses, in whom FDG-PET/CT was helpful in formulating a unifying diagnosis of metastatic seminoma, retrospectively corroborated by a history of testicular maldescent.

Case presentations

In all three cases, the patients were males aged in their 30s and 40s who were brought to medical attention for back and lower abdominal pain of varying duration. Initial imaging evaluation with computed tomography and/or ultrasound revealed large abdominopelvic soft tissue masses, with lymphoproliferative disorders or soft tissue sarcomas being high on the list of differential diagnoses.
As such, they were referred for staging FDG-PET/CT, all of whom demonstrated the pathognomonic constellation of, 1) unilateral absence of scrotal testicular activity, and 2) FDG-avid nodal masses along the typical testicular lymphatic drainage pathway. These characteristic patterns were corroborated by a targeted clinical history and examination which revealed a history of cryptorchidism, and elevated β-hCG in two of three patients. All were subsequently confirmed as metastatic seminoma on biopsy and open resection.

Conclusion

These cases highlight the importance of clinical history and examination for the clinician, as well as a sound knowledge of the typical testicular lymphatic drainage pathway for the PET physician, which would assist with prompt recognition of the characteristic imaging patterns on FDG-PET/CT. It further anecdotally supports the utility of FDG-PET/CT in evaluating undiagnosed abdominopelvic masses, as well as a potential role in the initial staging of germ cell tumours in appropriately selected patients.
Literature
1.
go back to reference Djaladat H, Nichols CR, Daneshmand S. Chemoresponsive liver hemangioma in a patient with a metastatic germ cell tumor. J Clin Oncol. 2011;29(35):e842–4.CrossRef Djaladat H, Nichols CR, Daneshmand S. Chemoresponsive liver hemangioma in a patient with a metastatic germ cell tumor. J Clin Oncol. 2011;29(35):e842–4.CrossRef
2.
go back to reference Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8(11):1777–81.CrossRef Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8(11):1777–81.CrossRef
3.
go back to reference Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–8.CrossRef Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–8.CrossRef
4.
go back to reference Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(4):242–53.CrossRef Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(4):242–53.CrossRef
5.
go back to reference Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356(18):1835–41.CrossRef Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356(18):1835–41.CrossRef
6.
go back to reference Toppari J, Kaleva M. Maldescendus testis. Horm Res. 1999;51(6):261–9.PubMed Toppari J, Kaleva M. Maldescendus testis. Horm Res. 1999;51(6):261–9.PubMed
7.
go back to reference Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol. 2004;22(1):2–14.CrossRef Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol. 2004;22(1):2–14.CrossRef
8.
go back to reference Thorup J, Mclachlan R, Cortes D, Nation T, Balic A, et al. What is new in cryptorchidism and hypospadias - a critical review on the testicular dysgenesis hypothesis. J Pediatr Surg. 2010;45:2074–86.CrossRef Thorup J, Mclachlan R, Cortes D, Nation T, Balic A, et al. What is new in cryptorchidism and hypospadias - a critical review on the testicular dysgenesis hypothesis. J Pediatr Surg. 2010;45:2074–86.CrossRef
9.
go back to reference Ferguson L, Agoulnik AI. Testicular cancer and cryptorchidism. Front Endocrinol. 2013;4:32.CrossRef Ferguson L, Agoulnik AI. Testicular cancer and cryptorchidism. Front Endocrinol. 2013;4:32.CrossRef
10.
go back to reference International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International germ cell Cancer collaborative group. J Clin Oncol. 1997;15(2):594–603.CrossRef International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International germ cell Cancer collaborative group. J Clin Oncol. 1997;15(2):594–603.CrossRef
11.
go back to reference Honecker F, Aparicio J, Berney D, et al. ESMO consensus conference on testicular germ cell cancer: diagnosis, treatment and follow up. Ann Oncol. 2018;29:1658–86.CrossRef Honecker F, Aparicio J, Berney D, et al. ESMO consensus conference on testicular germ cell cancer: diagnosis, treatment and follow up. Ann Oncol. 2018;29:1658–86.CrossRef
13.
go back to reference Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1053–68.CrossRef Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1053–68.CrossRef
14.
go back to reference Hick RJ. Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer? Cancer Imaging. 2012;12(2):315–23.CrossRef Hick RJ. Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer? Cancer Imaging. 2012;12(2):315–23.CrossRef
15.
go back to reference Hofman M, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16(1):35. Hofman M, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16(1):35.
16.
go back to reference Bouchelouche K, Choyke PL. PET/computed tomography in renal, bladder, and testicular cancer. PET Clin. 2015;10(3):361–74.CrossRef Bouchelouche K, Choyke PL. PET/computed tomography in renal, bladder, and testicular cancer. PET Clin. 2015;10(3):361–74.CrossRef
17.
go back to reference Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med. 1995;22(6):508–13.CrossRef Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med. 1995;22(6):508–13.CrossRef
18.
go back to reference Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol. 2001;40(5):481–7.CrossRef Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol. 2001;40(5):481–7.CrossRef
19.
go back to reference Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89(6):549–56.CrossRef Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89(6):549–56.CrossRef
20.
go back to reference Tsatalpas P, Beuthien-Baumann B, Kropp J, Manseck A, Tiepolt C, Hakenberg OW, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68(3):157–63.CrossRef Tsatalpas P, Beuthien-Baumann B, Kropp J, Manseck A, Tiepolt C, Hakenberg OW, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68(3):157–63.CrossRef
21.
go back to reference Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000;27(5):590–4.CrossRef Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000;27(5):590–4.CrossRef
22.
go back to reference Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology. 1999;53(4):808–11.CrossRef Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology. 1999;53(4):808–11.CrossRef
23.
go back to reference Cook GJ, Sohaib A, Huddart RA, et al. The role of 18F-FDG PET/CT in the management of testicular cancers. Nucl Med Comm. 2015;36(7):702–8.CrossRef Cook GJ, Sohaib A, Huddart RA, et al. The role of 18F-FDG PET/CT in the management of testicular cancers. Nucl Med Comm. 2015;36(7):702–8.CrossRef
24.
go back to reference de Wit M, Brenner W, Hartmann M, et al. 18F-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19(9):1619–23.CrossRef de Wit M, Brenner W, Hartmann M, et al. 18F-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19(9):1619–23.CrossRef
25.
go back to reference Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. Biomed Res Int. 2014;2014:852681.CrossRef Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. Biomed Res Int. 2014;2014:852681.CrossRef
26.
go back to reference de Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034–9.CrossRef de Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034–9.CrossRef
27.
go back to reference Cathomas R, Klingbiel D, Bernard B, et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell Cancer group registry. J Clin Oncol. 2018;36(34):3381–7.CrossRef Cathomas R, Klingbiel D, Bernard B, et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell Cancer group registry. J Clin Oncol. 2018;36(34):3381–7.CrossRef
28.
go back to reference Milowsky M. Genitourinary cancer. In: Hensley M, editor. ASCO-SEP 6th edition. Alexandria; 2018. Milowsky M. Genitourinary cancer. In: Hensley M, editor. ASCO-SEP 6th edition. Alexandria; 2018.
29.
go back to reference Pano B, Sebastia C, Bunesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics. 2011;31:135–60.CrossRef Pano B, Sebastia C, Bunesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics. 2011;31:135–60.CrossRef
30.
go back to reference Bose S, Sengupta S, Mukherjee R. Seminoma in an undescended testis. SM J Surg. 2017;3(2):1018. Bose S, Sengupta S, Mukherjee R. Seminoma in an undescended testis. SM J Surg. 2017;3(2):1018.
31.
go back to reference Yilmaz A, Bayraktar B, Sagiroglu J, Gucluer B. Giant seminoma in an undescended testis presenting as an abdominal wall mass. J Surg Case Rep. 2011;12:9.CrossRef Yilmaz A, Bayraktar B, Sagiroglu J, Gucluer B. Giant seminoma in an undescended testis presenting as an abdominal wall mass. J Surg Case Rep. 2011;12:9.CrossRef
32.
go back to reference Althaf S, Shankar K, Kurpad V, Suma MN. Seminoma of undesended testis with urinary bladder metastasis: a case report with review of literature. Urol Ann. 2017;9(1):77–9.CrossRef Althaf S, Shankar K, Kurpad V, Suma MN. Seminoma of undesended testis with urinary bladder metastasis: a case report with review of literature. Urol Ann. 2017;9(1):77–9.CrossRef
33.
go back to reference Carlotto J, Colleoni-Neto R, Shigueoka D, et al. Intra-abdominal seminoma testis in adult: case report. Arq Bras Cir Dig. 2015;28(4):296.CrossRef Carlotto J, Colleoni-Neto R, Shigueoka D, et al. Intra-abdominal seminoma testis in adult: case report. Arq Bras Cir Dig. 2015;28(4):296.CrossRef
Metadata
Title
The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!
Authors
Te-Jui Hung
Luke McLean
Catherine Mitchell
Claire Pascoe
Nathan Lawrentschuk
Declan G. Murphy
Amir Iravani
Dalveer Singh
Michael S. Hofman
Lamiaa Zidan
Tim Akhurst
Jeremy Lewin
Rodney J. Hicks
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2019
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-019-0217-5

Other articles of this Issue 1/2019

Cancer Imaging 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine